PMID- 31118798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting 
      the PI3K/Akt signaling pathway.
PG  - 3801-3812
LID - 10.2147/CMAR.S199291 [doi]
AB  - Purpose: In this study, we used a nude mouse model of human laryngeal squamous 
      cell carcinoma (LSCC) to investigate inhibition of tumor growth by microRNA-145 
      (miR-145) and the mechanisms underlying this inhibition. Methods: Tumors were 
      established in nude mice by transplantation of the LSCC AMC-HN-8 cell line. 
      Forty-eight nude mice were randomly divided into groups of eight mice each and 
      treated with high (1.0 optical density [OD]) or low (0.5 OD) doses of miR-145, or 
      relevant control treatments. Tumor growth was observed in each group and used to 
      calculate the inhibition rate. Routine pathological and electron microscopic 
      examinations were used to determine tumor apoptosis and proliferation. Changes in 
      levels of miR-145 and PI3K and Akt protein levels were also analyzed. Results: 
      MiR-145 inhibited LSCC growth in a dose-dependent manner, as tumor growth was 
      significantly inhibited in mice injected intratumorally with high-dose miR-145 
      compared with both the untreated and low-dose miR-145 groups (p<0.05). 
      Pathological examination showed increased tumor necrotic and apoptotic changes in 
      treated mice, which was confirmed by electron microscopy. PI3K and Akt protein 
      expression were significantly lower in tumors treated with high-dose miR-145 
      group compared with those in the untreated and low-dose miR-145 groups (p<0.05). 
      Conclusions: MiR-145 was associated with inhibited tumor growth in a nude mouse 
      model of LSCC. The underlying mechanism may be inhibition of the PI3K/Akt 
      signaling pathway, which regulates tumor growth, invasion, and metastasis and 
      also plays an important role in tumor angiogenesis and proliferation of tumor 
      stem cells. MiR-145 may act as a tumor suppressor gene and is a promising 
      candidate for cancer treatment.
FAU - Ye, Dong
AU  - Ye D
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated 
      Hospital of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Deng, Hongxia
AU  - Deng H
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Lin, Lexi
AU  - Lin L
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Zhou, Shuihong
AU  - Zhou S
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated 
      Hospital of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190430
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6500435
OTO - NOTNLM
OT  - animal model
OT  - laryngeal squamous cell carcinoma
OT  - mechanism
OT  - miRNA-145
OT  - oncology
OT  - treatment
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/05/24 06:00
MHDA- 2019/05/24 06:01
PMCR- 2019/04/30
CRDT- 2019/05/24 06:00
PHST- 2018/12/23 00:00 [received]
PHST- 2019/04/01 00:00 [accepted]
PHST- 2019/05/24 06:00 [entrez]
PHST- 2019/05/24 06:00 [pubmed]
PHST- 2019/05/24 06:01 [medline]
PHST- 2019/04/30 00:00 [pmc-release]
AID - 199291 [pii]
AID - 10.2147/CMAR.S199291 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Apr 30;11:3801-3812. doi: 10.2147/CMAR.S199291. 
      eCollection 2019.